|
|
| (11) | Liudijimo numeris | C 2662091 |
| (68) | Patento numeris | 2662091 |
| (21) | Paraiškos papildomos apsaugos liudijimui gauti numeris | PA 2021 506 |
| (22) | Paraiškos papildomos apsaugos liudijimui gauti padavimo data | 2021-04-13 |
| (41) | Paraiškos papildomos apsaugos liudijimui gauti paskelbimo data | 2021-05-10 |
| Liudijimo paskelbimo data | 2022-10-10 | |
| (24) | Liudijimo įsigaliojimo data | 2027-12-01 |
| (71) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
Oklahoma Medical Research Foundation, 825 N.E. 13th Street, Oklahoma City, OK 73104, US |
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
Oklahoma Medical Research Foundation, 825 N.E. 13th Street, Oklahoma City, OK 73104, US |
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (93) | EU/1/20/1476, 2020-10-28 |
| (94) | 2032-11-30 |
| (95) | Krizanlizumabas |
| PAL išduotas |